Edwards Lifesciences Corporation (NYSE:EW) : Traders are bullish on Edwards Lifesciences Corporation (NYSE:EW) as it has outperformed the S&P 500 by a wide margin of 1.51% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.88%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.23% in the last 1 week, and is up 3.15% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -31.16% from its 1 Year high price. On Apr 27, 2016, the shares registered one year high at $112.00 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $99.90 and the 200 Day Moving Average price is recorded at $92.58.
The stock has recorded a 20-day Moving Average of 5.55% and the 50-Day Moving Average is 3.28%.
Edwards Lifesciences Corporation (NYSE:EW): stock turned positive on Friday. Though the stock opened at $104.42, the bulls momentum made the stock top out at $105.42 level for the day. The stock recorded a low of $103.5 and closed the trading day at $104.72, in the green by 0.93%. The total traded volume for the day was 1,330,866. The stock had closed at $103.75 in the previous days trading.
In an insider trading activity, The officer (CVP, Japan & Intercontinental), of Edwards Lifesciences Corp, Wang Huimin had unloaded 13,650 shares at $98.44 per share in a transaction on July 5, 2016. The total value of transaction was $1,343,706. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.